Novo Nordisk’s patents on semaglutide, the active ingredient in Ozempic, are starting to expire. On today’s Big Take podcast, @davidgura talks to @naomikresge and @AmberTongPW about how the company is navigating a dire 2026 sales projection as generic versions are poised to upend.🎙️ Listen now: https://t.co/yT3DsoVeH6 ...

Novo Nordisk is predicting a 13% drop in sales in 2026. As the company’s patents on Ozempic expire, could cheaper, generic versions give the company a run for its money? Big Take host @davidgura talks to Bloomberg reporters @naomikresge and @AmberTongPW about what comes next https://t.co/HV0Hv3lWMT ...

Novo Nordisk and Eli Lilly are facing an uncomfortable new price point this week after a $49 weight-loss pill jolted the GLP-1 market. By launching a low-cost, compounded oral version of semaglutide, ... ...

Telehealth company Hims & Hers is launching a cheaper, off-brand version of the blockbuster weight loss pill WegovyFILE - This photo shows Novo Nordisk headquarters in Bagsvaerd, Denmark, on Feb. 5, 2025. (Mads Claus Rasmussen/Ritzau Scanpix via AP, File)WASHINGTON -- Telehealth company Hims & Hers said Thursday it will launch a cheaper, off-brand version of the weight-loss pill Wegovy, just weeks after drugmaker Novo Nordisk launched its highly anticipated reformulation of the blockbuster medication.The an ...

诺和诺德股份公司董事会成员、高管和关联人士买卖诺和诺德股票。 来源：滚动播报 ...

Hims Stock Slides After Launching Oral Wegovy Knockoff; Novo, Lilly Tumble | Investor's Business DailySPECIAL REPORT: [Find The Online Broker That Best Fits Your Needs]---Hims & Hers Health (HIMS) launched a compounded version of Novo Nordisk's (NVO) already popular weight-loss pill on Thursday. But Hims stock reversed its early gains, while Novo and Eli Lilly (LLY) continued falling. The compounded pill will cost just $49 for the first month, roughly $100 less than what Novo Nordisk is charging for its ora ...

Novo Nordisk said it plans to take legal and regulatory action against Hims & Hers. https://t.co/vz8z9EOZQN ...

Core Insights - The weight loss drug market is experiencing a significant divergence between Eli Lilly and Novo Nordisk, with Eli Lilly gaining market share while Novo Nordisk is facing challenges [1][2][5] Company Performance - Eli Lilly's revenue increased by 40%, with guidance for over $80 billion in revenue for the next year, significantly exceeding expectations [4] - In contrast, Novo Nordisk's stock has declined over 45% year-over-year, and they are projecting revenue declines in 2026 [2][5] Market Dynamics - Eli Lilly's GLP-1 franchise is strengthening, with their product Zepbound being the most effective on the market, which is a key driver of their performance [5][8] - The introduction of new pills in the market is attracting new customers, with 80% of users being new to the GLP-1 market [10][11] Competitive Landscape - Both companies are facing price pressures due to an intensifying price war in the weight loss drug sector [6] - Eli Lilly is expected to continue benefiting from Medicare coverage and increasing demand for its drugs [12][13] Financial Outlook - Eli Lilly is investing heavily in manufacturing, supported by strong cash flow, which is expected to reduce financial leverage over time [14] - The potential for mergers and acquisitions (M&A) poses a risk to Eli Lilly's credit metrics, although they have a conservative track record in this area [15]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists across key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered by the company includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Utilization - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company employs automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans to maintain quality and best practices in content production [5]

来源：环球市场播报 诺和诺德的最新指引意味着，该公司今年将录得九年来首次年度销售下滑，上次这样下滑还是在2017 年，当时是美国胰岛素市场的价格战所致。 诺和诺德CEO Mike Doustdar表示，2026年诺和诺德将在竞争日益激烈的市场中面临定价压力。虽然全 球GLP-1市场预计将继续扩张，但美国总统特朗普推动的"最惠国价格"政策，以及司美格鲁肽在多个国 际市场专利到期的影响，将对营收造成显著冲击。 诺和诺德（NVO）周四早盘下跌6.3%，此前该公司警告美国定价压力与专利到期风险。 ...